Compare KB Financial Group, Inc. (KB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs TransMedics Group Inc — how do they compare? KB Financial Group, Inc. trades at $117.53 (market cap $41.21B), while TransMedics Group Inc trades at $89.69 (market cap $3.10B). The key difference: KB Financial Group, Inc. is far larger — about 13.3× TransMedics Group Inc's market cap, and KB Financial Group, Inc. pays a 2.67% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| KB | TMDX | |
|---|---|---|
Market Cap | $41.21B | $3.10B |
Sector | Financials | Technology |
52-Week High | $124.01 | $150.42 |
52-Week Low | $77.50 | $61.99 |
Dividend Yield | 2.67% | — |
Enterprise Value | — | $3.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
